High blood pressure: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• AMPK 0
• SGLT2 3
• GLP-1 2
• PPAR 0
• AKT 0
• NLRP3 0
• PI3K 0
• NRF2 1
• HIF-1 0
• STAT3 0
• VEGF 0
• ACE2 0
• SIRT1 0
• TNF 1
• IL-6 1
• mTOR 0
• TLR4 0
• ERK 0
• MAPK 0
• HMGB1 0
• YAP 0
• CXCR4 0
• HSP90 0
• IL-17 1
• AR 1
• PCSK9 3
• APOE 1
• CD19 0
• GPX4 0
• JNK 0
• METTL3 0
• PINK1 0
• PTEN 0
• TP53 0
• ABL1 0
• APOL1 0
• BTK 2
• CD40 0
• FAK 0
• HDAC 0
• IL-1 0
• JAK 0
• MMP-9 0
• PKM2 0
• STK11 0
• CGRP 0
• CTNNB1 0
• DPP-4 0
• FTO 0
• RUNX1 0
• STING 0
• AXL 0
• CD38 0
• COX-2 0
• DMD 0
• GIP 0
• HTT 0
• IDH 0
• IGF1R 0
• MDM2 0

24 of 391 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• U.S. Department of Veterans Affairs · IK1

  Evaluating hypertension care delivery in Veterans with rheumatoid arthritis to improve cardiovascular disease prevention

  Durham Va Medical Center· Durham, United States· until Oct 2028

• U.S. Department of Veterans Affairs · IK6

  ISRM Research Career Scientist Award Application

  Veterans Health Administration· Pittsburgh, United States· until Sept 2031

• NIH NEI · R01

  Mobile Strategy for Improving Eye Health of Kidney Patients Treated with Dialysis (SIGHT)

  University of Washington· Seattle, United States· US$1,383,760 awarded in fiscal year 2026· until Aug 2031

• NIH NIDDK · F31

  Examining Real-World Uptake and Effectiveness of GLP-1 RA in an Urban Population with Type-2 Diabetes

  New York University School of Medicine· New York, United States· US$36,947 awarded in fiscal year 2026· until Sept 2028

• NIH NEI · R43

  Novel Ocular Aerosol Drug Delivery Device for the Treatment Optimization of Glaucoma.

  Via Therapeutics, Llc· Austin, United States· US$277,143 awarded in fiscal year 2026· until Sept 2027

• European Commission (Horizon Europe) · HORIZON-ERC

  Selective Sensory Vagal Interface: a bionic platform for internal organ modulation (VisceraLink)

  Medizinische Universitaet Wien· Wien, Austria· EU contribution €2,210,625· until Dec 2031

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Design and development of explainable DL/ML model for medical image analysis with high accuracy and reliability (MED-XAI)

  Universidade Nova de Lisboa· Lisboa, Portugal· EU contribution €207,183· until Dec 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Pulmonary Hypertension in COPD : from Observation to Emerging Novel therapeutic Insights and eXploration (PHOENIX)

  Universitat Zurich· Zurich, Switzerland· EU contribution €292,119· until Dec 2028

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Birth and Labor Outcome Optimization through Multimodal AI (BLOOM)

  Universita Degli Studi Gabriele D'annunzio di Chieti-Pescara· Chieti, Italy· EU contribution €321,949· until May 2029· 3 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Unveiling Dynamic Autonomic Regulation in health and disease through Network Physiology (DARNePh)

  Univerzita Komenskeho V Bratislave· Bratislava 1, Slovakia· EU contribution €172,942· until Aug 2028· 2 countries

  The disease is named only in the funder's project summary, not in the title.

10 of 3,621 running projects, newest first. Listed amounts together: US$2.2bn + €231.7m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)

  NCT04968184· Novo Nordisk A/S· Updated 4 Nov 2026

  “Interim futility analysis showed primary endpoint not achieved”Registry text, quoted unchanged. Source

• Terminated

  mHealth for Hypertensive Disorder of Pregnancy

  NCT05995106· Seoul National University Hospital· Updated 2 Nov 2026

  “Maintenance of the Heart4U application was discontinued, and enrollment was stopped.”Registry text, quoted unchanged. Source

• Withdrawn

  Fixed-dose Combination of an Angiotensin Receptor Blocker and Thiazide Diuretic for Essential Hypertension

  NCT06608472· Eurofarma Laboratorios S.A.· Updated 26 Oct 2026

  “Strategic change in development priorities.”Registry text, quoted unchanged. Source

• Terminated

  Baroloop Multicenter Trial (Baroloop MCT)

  NCT06518915· neuroloop GmbH· Updated 20 Oct 2026

  “Terminated following a device deficiency in 1 subject. Benefit-risk and development assessments did not support continuation within the planned framework. Root cause analysis pending.”Registry text, quoted unchanged. Source

• Terminated

  Blood PREssure Augmentation in Large-vessel Occlusion Stroke Study

  NCT04218773· Yale University· Updated 14 Oct 2026

  “The study was terminated prematurely due to lack of continued funding.”Registry text, quoted unchanged. Source

• Terminated

  Role of L-citrulline in Prevention of Pregnancy Associated Hypertension

  NCT04979793· The University of Texas Medical Branch, Galveston· Updated 30 Sept 2026

  “At the request of the PI”Registry text, quoted unchanged. Source

• Withdrawn

  A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease

  NCT07223502· Sarfez Pharmaceuticals, Inc.· Updated 22 Sept 2026

  “No recruitment”Registry text, quoted unchanged. Source

• Withdrawn

  Glucagon-like Peptide-1 Metabolism and Acute Neprilysin Inhibition

  NCT03508739· University of Pennsylvania· Updated 21 Sept 2026

  “We do not have active funding.”Registry text, quoted unchanged. Source

• Withdrawn

  Glucose and Blood Pressure During Pregnancy

  NCT04979312· Mayo Clinic· Updated 15 Sept 2026

  “Device Unavailable”Registry text, quoted unchanged. Source

• Terminated

  Contributions to Hypertension With Androgen Deprivation Therapy

  NCT05700903· University of Colorado, Denver· Updated 2 Sept 2026

  “Study completed”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Boehringer Ingelheim· Source

• Feasibility of Remote Blood Pressure Monitoring to Improve Management of Hypertensive Disorders of Pregnancy

  NCT07930494· Sanford Health· Source

• Emergency Department-Initiated Team-Based Care for Severe Hypertension

  NCT07777237· Henry Ford Health System· Source

• Tailored Education for Aging and Cognitive Health: A Health Behavior Change Intervention for Midlife Adults at Risk for Alzheimer's Disease and Related Dementias

  NCT07933367· Rhode Island Hospital· Source

• Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

  NCT07181109· Alnylam Pharmaceuticals· Source

• A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran

  NCT07553442· Alnylam Pharmaceuticals· Source

• HYPERtension Reduction Through WALKing Stairs Versus Brisk Walking

  NCT06952348· Karolinska Institutet· Source

• Remote Hypertension Management for Black Patients

  NCT06527794· Wake Forest University Health Sciences· Source

• Implementation Support for HEARTS-Based Hypertension and Diabetes Care in Guatemala

  NCT07536919· University of Michigan· Source

• Carotid Ultrasound-based Assessment of Maternal Hemodynamics to Guide HYpertension Treatment in PREgnancy - Pilot Study

  NCT07932171· Assistance Publique - Hôpitaux de Paris· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 12
• Organoids 1
• Mendelian Randomization Analysis 85
• CRISPR-Cas Systems 2
• Gene Expression Profiling 52
• Sequence Analysis, RNA 5
• Whole Genome Sequencing 2
• Exome Sequencing 11
• Proteomics 45
• Metabolomics 45
• Mass Spectrometry 3
• Flow Cytometry 4
• Immunohistochemistry 24
• Liquid Biopsy 1
• Xenograft Model Antitumor Assays 1
• Positron-Emission Tomography 6
• Magnetic Resonance Imaging 125
• Machine Learning 101
• Deep Learning 13
• Cohort Studies 416
• Genome-Wide Association Study 82

• PET Imaging in Pulmonary Hypertension.

  Arterioscler Thromb Vasc Biol, Oct 2026

• Primary Aldosteronism: CXCR4- and FAP-Targeted PET/MR for Adrenal-Cardiac Axis.

  Circ Cardiovasc Imaging, Jun 2026

• Right ventricular metabolic adaptation to afterload and heterogeneous right ventricular-pulmonary arterial coupling in pre-capillary pulmonary hypertension: An 18F-fluorodeoxyglucose positron emission tomography /cardiac magnetic resonance study.

  J Nucl Cardiol, Jun 2026

• Current perspectives on imaging modalities in the diagnosis and management of pulmonary hypertension.

  Respir Investig, Feb 2026

• Hypertension is the Main Vascular Risk Factor for Cognitive Impairment, Microvascular Pathology and Brain Atrophy in Alzheimer's Disease.

  Curr Alzheimer Res, Jan 2026

• Fasting 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography to detect metabolic changes in pulmonary arterial hypertension hearts over 1 year.

  Ann Am Thorac Soc, Feb 2013

See which targets of this disease your abstract mentions, and go to the people working on them.